Isolating Bronchial Epithelial Cells from Resected Lung Tissue for Biobanking and Establishing Well-Differentiated Air-Liquid Interface Cultures
May 26th, 2023
5.8K views
Presented here is a reproducible, affordable, and robust method for the isolation and expansion of primary bronchial epithelial cells for long-term biobanking and the generation of differentiated epithelial cells by culture at the air-liquid interface.
Overview
This article presents a robust and cost-effective method for isolating and expanding primary bronchial epithelial cells (PBECs) for long-term biobanking and differentiation at the air-liquid interface. The technique allows for the study of airway epithelial cell functions in health and disease.
Key Study Components
Area of Science
- Neuroscience
- Cell Biology
- Respiratory Health
Background
- Airway epithelial cells play a crucial role in respiratory health.
- Understanding their function can help address various diseases.
- Current methods for studying these cells can be expensive and complex.
- This study aims to provide a more accessible approach.
Purpose of Study
- To develop a reproducible method for isolating PBECs.
- To enable long-term storage and differentiation of these cells.
- To facilitate research on airway epithelial cell responses to various stimuli.
Methods Used
- Isolation of bronchial rings from human lung tissue.
- Cell culture at the air-liquid interface.
- Assessment of cell layer integrity using TEER measurements.
- Comparison of different media and supplements for optimal growth.
Main Results
- Successful generation of a cell layer mimicking human airway epithelium.
- TEER values above 300 ohms indicate healthy cultures.
- Variability in cell composition based on media and donor sources.
- Maximal TEER achieved with specific concentrations of EC 23.
Conclusions
- The method provides a reliable way to study airway epithelial cells.
- It allows for the exploration of disease mechanisms and therapeutic responses.
- Further optimization can enhance the reproducibility of results.
Frequently Asked Questions
What are primary bronchial epithelial cells?
Primary bronchial epithelial cells are cells that line the airways and play a key role in respiratory health.
How is the cell culture maintained?
The cell culture is maintained at the air-liquid interface with regular medium changes to support growth.
What is TEER and why is it important?
TEER stands for transepithelial electrical resistance, and it is a measure of the integrity of the cell layer.
Can this method be used for other types of epithelial cells?
While this method is optimized for bronchial epithelial cells, similar techniques may be adapted for other epithelial types.
What are the advantages of this method?
This method is cost-effective, reproducible, and provides a good representation of human airway epithelium.
How long can PBECs be stored?
PBECs can be cryopreserved for long-term storage in liquid nitrogen.
Executive Industry Relevance
Establishing well-differentiated air-liquid interface (ALI) cultures from primary bronchial epithelial cells (PBECs) enables predictive modeling of airway biology for respiratory drug discovery. This protocol supports robust, donor-representative in vitro systems critical for target validation, mechanistic de-risking, and translational continuity in respiratory R&D portfolios. Biobanking of PBECs further enhances reproducibility and scalability across discovery and preclinical workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of airway epithelial responses to disease-relevant insults and therapeutic candidates.
- Supports functional target validation by modeling mucus production and ciliary activity in human-relevant systems.
- Facilitates mechanistic de-risking by allowing controlled exposure to toxicants, infectious agents, or inflammatory mediators.
- Provides a platform for comparative analysis of donor variability and media effects on epithelial differentiation.
Screening & Assay Development
- Delivers standardized, reproducible ALI cultures suitable for quantitative readouts such as TEER and gene expression.
- Enables preparation of validated biological systems for downstream screening of inhaled therapeutics or environmental exposures.
- Supports assay scalability and platform reuse through biobanking and cryopreservation of PBECs.
- Facilitates reliable evaluation of compound effects on epithelial barrier integrity and cellular composition.
Translational & Preclinical Research
- Provides disease-relevant in vitro models for studying airway pathogenesis and therapeutic intervention.
- Enables alignment with translational biomarkers through cell-type specific marker gene analysis.
- Supports continuity from early discovery to preclinical validation by maintaining donor-specific biological characteristics.
- Allows integration of additional cell types for enhanced tissue representation in advanced models.
Pipeline & Workflow Integration
This protocol positions ALI-PBEC cultures as a foundational tool from early discovery through preclinical research, supporting hypothesis testing, screening, and translational studies in respiratory drug development.
- Discovery Biology: Facilitates hypothesis-driven interrogation of airway epithelial function and response to stimuli.
- Screening: Provides reproducible, quantitative outputs such as TEER for assay standardization and compound evaluation.
- Analytics: Enables measurement of gene expression, mediator production, and barrier integrity for comparative analysis.
- Translational Research: Maintains donor-specific features and supports biomarker alignment for preclinical studies.
- Enterprise Reuse: Biobanking of PBECs allows for repeated, standardized use across multiple projects and teams.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in airway disease modeling.
- Operational Value: Enhances standardization, reproducibility, and scalability of epithelial cell culture workflows.
- Strategic Value: Improves go/no-go decision-making and capital efficiency by enabling robust in vitro validation.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory therapeutic candidates.
Implementation Considerations
- Requires expertise in primary cell isolation, culture, and differentiation techniques.
- Needs access to specialized cell culture infrastructure and analytical tools for TEER and gene expression analysis.
- Demands cross-team standardization of media, supplements, and culture conditions to minimize variability.
- Adaptation may be necessary for integration with additional cell types or disease-specific models.
- Donor variability and media source can influence cellular composition and functional readouts.
Biopharma FAQs
Why does null hypothesis testing matter for TEER-based target validation?
Null hypothesis testing using TEER measurements enables objective assessment of whether experimental conditions or interventions significantly alter epithelial barrier integrity. This statistical rigor is essential for validating targets and reducing false positives in airway drug discovery.
How does independent variable isolation fit ALI-PBEC exposure studies?
Isolating independent variables, such as media composition or EC 23 concentration, allows teams to attribute observed changes in differentiation or TEER directly to specific experimental factors. This clarity supports mechanistic de-risking and robust interpretation of airway model outputs.
What do quantitative TEER and gene expression measurements enable?
Quantitative TEER and gene expression outputs provide reproducible, comparable metrics for evaluating epithelial barrier function and cell-type composition. These measurements support cross-condition analysis and inform go/no-go decisions in respiratory R&D pipelines.
Why are replication requirements critical for cross-functional ALI culture use?
Replication ensures that ALI-PBEC culture results are consistent across donors, media, and experimental runs, enabling reliable data sharing and collaboration between discovery, screening, and translational teams. This reproducibility underpins enterprise-wide confidence in model outputs.
What statistical analysis capabilities are required before ALI-PBEC implementation?
Teams must be equipped to perform statistical comparisons of TEER, gene expression, and cellular composition across experimental groups. This capability is necessary to validate model performance, assess donor variability, and support data-driven advancement decisions.
Chapters in this video
0:04
Introduction
0:47
Isolation of Bronchial Epithelial Cells from Human Lung Tissue
2:17
Cryopreservation of Human Primary Bronchial Epithelial Cells (PBECs)
3:28
Thawing Cryopreserved PBECs and Growing Them for Culture on Inserts
4:23
Establishing an Air‐Liquid Interface Culture with Primary Bronchial Epithelial Cells (ALI‐PBEC)
6:03
Results: Characterization of ALI Cultures Using Cell‐Specific Marker Genes
7:41
Conclusion
